07/19/2016 - 2:36pm
Ajanta’s Axert generics will be available in 6.25- and 12.5-mg dosage strength. 
 
07/18/2016 - 11:51am

ANI’s is the first generic of the Nilandron, which is indicated to treat metastatic prostate cancer in combination with surgical castration. 

07/18/2016 - 11:42am

The drug had U.S. sales of about $306.7 million for the 12 months ended May 2016, according to IMS Health. 

07/15/2016 - 11:57am

In addition to leveraging a pipeline of complex generics across its markets while focusing on OTC, Dr. Reddy's chairman K Satish Reddy said the branded generics would be one of the ways the company drives growth in the coming years.

07/13/2016 - 11:53am
Reuters is reporting that the FDA’s Arthritis Advisory Board has unanimously recommended Amgen’s biosimilar of AbbVie’s Humira, ABP 501. The panel said that the drug was similar in safety and effectiveness to Humira for rheumatoid arthritis and plaque psoriasis, and it recommended that the biosimilar should also be approved for Crohn’s disease in adults and ulcerative colitis. (Reuters)
07/12/2016 - 2:43pm

The move is aimed at Nichi-Iko becoming one of the top 10 global generics leaders, and the companies said acquiring Sagent will boost Nichi-Iko’s ability to commercialize its biosimilar pipeline and increase its presence in injectables.

07/12/2016 - 1:59pm

The agency has acted on 90% of the generic drug and prior approval supplement applications pending as of Oct. 1, 2012 — which puts it more than a year ahead of its final deadline of Sept. 30, 2017. 

07/06/2016 - 11:47am

Mylan’s fenofibrate tablets will be available in 40- and 120-mg dosage strengths. 

07/05/2016 - 11:30am

For the quarter, the company saw revenues of $723.6 million — a 1.6% rise over the same quarter last year that it attributes to overall market growth and the expansion of its franchised store network.